Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06385964 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients | PHASE1 | COMPLETED | 62 | — | — | May 7, 2024 | Feb 19, 2025 | Mar 6, 2026 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| SHR-4597 | EXPERIMENTAL | - |
| SHR-4597 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SHR-4597 | DRUG | SHR-4597 by dry powder inhalation |
| Placebo | DRUG | Placebo by dry powder inhalation |
Inclusion Criteria: \- Healthy subjects: * Understand the specific procedures of the trial, voluntarily participate in this trial, and sign the informed consent form in writing. * Aged between 18 and 55 years old (inclusive of boundary values). * Male subjects with a weight of ≥ 50 kg and female ...